An Asset Sale - The World�s First And Only Primary Hemost

Submitted 4 years ago

I am Intellectual Property and Asset Agent to Leon Wortham Owner of IP and CEO of Wortham Laboratories, Tennessee, USA (http://worthamlabs.com/secure_landing), presenting you herein an asset purchase opportunity, including the intellectual property with the CE license.

The value proposition of purchase of IP of SeraSeal® is available for global rights purchase. The proprietary IP of SeraSeal® is protected from replication and has no lifetime limits.

SeraSeal® is A PRIMARY HEMOSTATIC AGENT CAPABLE OF:

control all forms of bleeding quickly without destroying tissue
to use immediately without any preparation time
get the product to any part of body, even to closed systems with multiple delivery systems
be extremely effective in the presence of anticoagulant drugs and coagulopathies (bleeding disorders)

SeraSeal® is a the only CE licensed primary hemostatic agent registered in 47 countries as the first line of defense to arrest bleeding in in closed wounds, such as gunshots, stabbings, or impaled wounds, and open large gaping wounds, and surgical bleeding and used in military, by paramedics, emergency/trauma center personnel, and law enforcement for immediate stopping of venous or arterial bleedings, even in the presence of anticoagulant therapy drugs and in patients with bleeding disorders.

All competitor hemostatic and tissue sealing products are only able to arrest bleed in minutes as compared to ONLY SECONDS with SeraSeal®. As well hemostatic agents on the market are adjunct or secondary products, which are added after the bleeding is controlled and their use is limited to surgical procedures. This suboptimal treatment puts patients at risk of dying of injuries and surgical procedures.

The market size of global hemostasis and tissue sealing products was valued at $5.35 Billion (USD) in 2018. Market is anticipated to expand at a CAGR of 8.7% annual rate during the 7-year forecast period.

It is simple and safe to administer by oneself or anyone also topically with FOAM formulation. Therefore the market for SeraSeal® is very large when it enters the consumer market in the form of first-aid products for the home, business, recreational and sporting events.

Surely this is a major business opportunity to your company. If you company produces only pharmaceutical products and not medical devices, you will obtain not only the IP, but also the
full quality assurance program (ISO 13485 Certificate) for medical device and the transfer of the CE license.

SeraSeal® is capable of reducing surgical time by 50%, eliminates blood transfusion by 90%, and reduces anesthetic and pain medication. Efforts to reduce health care costs are actively pursued worldwide by government health care agencies, private hospitals, medical and surgical clinics, and insurance companies.

Efficacy vs competitors is presented in the Journal of Gastroenterology, July 2015, and Journal of Cranio-Maxillo-Facial Surgery, June 2016 attached.

Please find attached a 2-page summary, which has details of this worldwide asset purchase opportunity.

To further discuss your interest to purchase the IP assets and certification transfer, please contact me by responding to this email address or by phone.

Looking forward to hearing from you very soon.

Best regards,

Jukka

Jukka Karjalainen, MD, PhD

CEO, President and Director
PHARMA CONSULTING SERVICES (PCS) INC.

Professor
Senior Lecturer and Registrar
Board Certified in Pharmaceutical Medicine
Board Certified in Pediatrics
Board Certified in Diabetes Research and Care
Board Certified in General Medicine

LPH5-2230 Lakeshore Blvd West
Toronto, Ontario, Canada M8V 0B2
Tel: +1-416-358-4495
Fax: 1888-852-8572
Email: [email protected]